BPC-157 Dosage: What People Use (and What's Actually Unknown)

Search "BPC-157 dosage" and you will find confident, precise-sounding protocols: 250 to 500 micrograms a day, injected near the injury, for four to eight weeks. The numbers look clinical. They are not. There is no established, FDA-validated human dose for BPC-157, because there is no FDA-approved BPC-157 product and no completed human dosing trial. Every protocol circulating online is an extrapolation — usually from rat studies, sometimes from one vendor copying another. This article lays out what those numbers actually are, where they come from, and the large gap between "a dose people use" and "a dose proven safe and effective in humans."

We are not going to give you a protocol to follow. This is not medical advice, BPC-157 is an unapproved research chemical, it is banned in tested sport, and the dosing question is genuinely unanswered. What follows is the honest version of what's known.

The Honest Headline: No Validated Human Dose Exists

Start with the single most important fact, because everything else depends on it. A 2026 biopharmaceutical review of BPC-157's drug-development status concluded that despite more than three decades of preclinical research, its pharmaceutical development "remains rudimentary, with no approved formulation, no validated dosing regimen, and no completed Phase II clinical trial"¹. Read that again: no validated dosing regimen. That is the state of the science as of 2026, from a review that searched the regulatory databases of the FDA, EMA, and WADA directly.

So when a vendor or forum gives you "the standard dose," understand what that phrase is hiding. There is no standard. There is no dose-finding study in humans establishing what works, what's safe, or where the ceiling is. The confident numbers are borrowed — and the place most of them are borrowed from is the animal literature.

Where the Common Numbers Actually Come From

BPC-157's animal studies do use specific doses, and this is the well most online protocols draw from. In the rodent work, effective doses are typically reported in micrograms or even nanograms per kilogram of body weight — for example, the rat tendon, muscle, and angiogenesis studies that form the core of the healing literature dosed the peptide in the low microgram-per-kilogram range, given intraperitoneally or intramuscularly⁵⁶⁷. A rat is not a person, and a dose that heals a transected rat Achilles tendon⁵ tells you nothing reliable about what a human tendon needs, or tolerates.

Here is where the extrapolation goes wrong in a specific, checkable way. People take a rat dose in micrograms-per-kilogram and either scale it directly to their body weight or — more often — just adopt a flat "250–500 mcg/day" that has drifted into the community as folklore. Direct body-weight scaling between species is not how pharmacology works; allometric differences in metabolism mean a rat dose does not translate to an equivalent human dose by simple multiplication. And the flat folklore numbers have no derivation at all. Neither approach is anchored to a human study, because no human dosing study exists¹⁸.

Why Pharmacokinetics Make "A Dose" Hard to Even Define

Even setting aside efficacy, there's a mechanical problem with stating a BPC-157 dose: the peptide does not stay around long. The only formal pharmacokinetic (ADME) study, conducted in rats and beagle dogs, found that BPC-157's plasma elimination half-life is under 30 minutes, with intramuscular bioavailability ranging from roughly 14% in rats to about 45–51% in dogs, after which it is rapidly broken down into small peptide fragments and amino acids and cleared through urine and bile². The kinetics were linear across the doses tested².

A sub-30-minute half-life matters for dosing in a way the protocols ignore. It means any "once-daily" injection leaves the peptide present in the blood for only a small fraction of the day. The 2026 review flags exactly this — a pharmacokinetic-pharmacodynamic "disconnect," where the compound's reported biological effects don't line up neatly with how briefly it actually circulates¹. That disconnect is part of why nobody can yet say what an effective human dosing schedule would even look like. You cannot rationally pick a dose and frequency for a drug whose exposure-response relationship in humans has never been measured.

The injection-site folklore ("pin near the injury") leans on the idea that local concentration matters more than systemic levels — plausible given the short half-life, and consistent with the local angiogenesis seen in animal tendon and muscle models⁶⁷. But "plausible mechanism" is not "validated protocol," and local injection of an unregulated peptide carries its own contamination and tissue-reaction risks.

Oral, Subcutaneous, Intramuscular: The Route Question Is Also Unsettled

BPC-157 is sold as injectable vials, oral capsules, and even nasal sprays, and protocols differ by route — which would only make sense if the route-specific human absorption were known. It isn't. The peptide is unusually stable in gastric juice, which is why oral BPC-157 is even plausible, and animal work does show activity by oral, parenteral, and topical routes¹³. But "shows some activity in animals by multiple routes" is a long way from "here is the oral-equivalent of an injected dose in a human." The formal review is blunt that the human pharmacokinetic profile across routes remains "critically undercharacterized"¹.

So the oral-vs-injectable dose conversions you'll see quoted are invented. There is no human bioavailability study to convert between them.

What "Side Effects at Dose X" Even Means Here

People reasonably want to know the dose ceiling — the level above which harm appears. For BPC-157, that question has no human answer either. The animal literature actually reports BPC-157 as well-tolerated and even protective in some toxicity models, and reviews describe a generally favorable preclinical safety signal⁴⁸. That sounds reassuring, and it is routinely quoted as if it were a human safety clearance. It is not. Rodent tolerability does not establish a human safe dose, a human maximum tolerated dose, or long-term human safety — none of which have been studied¹⁹. The absence of reported harm in short rat studies is not the same as evidence of safety in people using it for months.

And the practical dosing risk most protocols never mention is the vial itself. Because no approved, quality-controlled BPC-157 product exists, the actual amount of peptide in a "5 mg" research-chemical vial is unverifiable; independent testing of grey-market peptides has repeatedly found identity, purity, and content inconsistencies. So even a person trying to follow a specific microgram dose may be drawing up a wildly different amount than the label claims. Precise dosing of an imprecise product is a false comfort. We cover this supply problem in depth in our review of BPC-157's healing evidence and our look at whether GH peptides are safe and legal.

The Two Facts That Sit Above Any Dose

Before anyone reasons about milligrams, two non-negotiable facts apply at every dose.

It is not an FDA-approved drug. In 2023 the FDA placed BPC-157 among the bulk drug substances that may present significant safety risks, effectively keeping it off the list pharmacies may legally compound for human use¹⁰. There is no approved finished product to dose.

It is banned in tested sport at any dose. The U.S. Anti-Doping Agency states BPC-157 is prohibited under the WADA Prohibited List in category S0 (Unapproved Substances), banned at all times, in and out of competition¹¹. For a drug-tested athlete, no dose is "safe" — a positive test is a violation regardless of how little was used. We unpack the anti-doping picture in our guide to GH peptides for athletes, and the popular pairing question in our BPC-157 + TB-500 stack review — where, notably, no human study tests either dose alone, let alone combined.

Bottom Line

The honest answer to "what is the BPC-157 dosage?" is: nobody knows, because it has never been established in a human trial. The numbers you see — 250 to 500 micrograms a day, near the injury, for a few weeks — are folklore extrapolated from rat studies and copied between vendors, untethered from any human dose-finding research. The one formal pharmacokinetic study shows the peptide clears in under half an hour with route-dependent bioavailability that was measured in rats and dogs, not people², and the most recent drug-development review states flatly that there is no validated dosing regimen¹.

Layer on top of that an unverifiable grey-market supply, an FDA bulk-substance flag, and a blanket WADA ban, and the dosing conversation collapses into a simpler one: this is an unproven, unapproved, banned peptide with no human-established dose. The animal science is a reason to run human trials, not a license to pick a number and inject it. For how BPC-157 ranks against the rest of the field, see our evidence-ranked guide to the best recovery peptides, and for the broader recovery-claims picture, our peptides for muscle growth review.